HROW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Harrow Inc (HROW) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The business fundamentals are improving on revenue growth, but the current setup is mixed: technicals are neutral, options sentiment is bullish, but analyst targets have recently been reduced and there is no fresh news catalyst. Since you want a direct answer and are not waiting for an ideal entry, my view is to hold off on buying today and wait for a clearer confirmation of earnings-driven upside.
Price is trading near 40.51 in pre-market, slightly below the pivot at 40.037 but still below the first resistance at 41.687. MACD histogram is positive but contracting, which suggests momentum is still mildly constructive but weakening. RSI_6 at 59.913 is neutral-to-moderately bullish, not overbought. Moving averages are converging, pointing to a lack of strong trend conviction. Overall, the chart shows a sideways-to-mildly bullish structure, but not a clean breakout setup. The near-term pattern data also points to a bearish short-term bias, with estimated downside over the next week and month.
["Revenue in 2025/Q4 increased 33.31% YoY, showing strong top-line growth.", "Gross margin improved to 79.27%, indicating strong product economics.", "Analyst coverage remains broadly constructive, with multiple Buy/Overweight ratings still in place.", "Options data shows strong bullish sentiment via low put-call ratios.", "No negative news flow in the recent week."]
["No recent news catalysts in the last week, so there is no immediate event-driven upside.", "Several analysts cut price targets recently, including reductions from B. Riley, Ladenburg, Cantor Fitzgerald, and Lake Street.", "Net income fell 2.23% YoY and EPS fell 5.26% YoY in the latest quarter, showing earnings lagging revenue growth.", "Technical momentum is not strong enough for an aggressive entry: MACD is positive but contracting and moving averages are converging.", "Short-term stock pattern data suggests negative next-day, next-week, and next-month performance probabilities."]
In 2025/Q4, Harrow delivered strong revenue growth to $89.09M, up 33.31% YoY, and gross margin expanded to 79.27%. However, profitability was softer: net income declined 2.23% YoY to $6.63M and EPS fell 5.26% YoY to $0.18. This is a healthy growth quarter on the top line, but earnings quality is not yet fully matching the revenue acceleration.
Wall Street remains mostly positive, with B. Riley, Ladenburg, Cantor Fitzgerald, Lake Street, and H.C. Wainwright all maintaining Buy/Overweight-type ratings. The recent trend, however, is downward on price targets: B. Riley cut to $65 from $74, Ladenburg to $62 from $66, Cantor to $91 from $94, Lake Street to $60 from $70, and H.C. Wainwright nudged up to $70 from $69. The pros view is still constructive on the business, but the lower targets show some caution around near-term execution and revenue timing.
